234 results on '"Cipolla, David"'
Search Results
2. Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.
3. Controlling the size and shape of liposomal ciprofloxacin nanocrystals by varying the lipid bilayer composition and drug to lipid ratio
4. Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation
5. Drug nanocrystallisation within liposomes
6. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis
7. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species
8. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice
9. Soft Mist Inhalers
10. Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
11. Additional file 1 of Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
12. Inhaled nicotine replacement therapy
13. Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection.
14. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-a-accelerated lupus nephritis in mice.
15. Correction for Plaunt et al., “Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections”
16. Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug
17. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
18. An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells
19. Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans
20. Modifying the Release Properties of Liposomes Toward Personalized Medicine
21. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation
22. Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation
23. Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection
24. Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
25. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension
26. Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery
27. Inhaled Medicines: Past, Present, and Future
28. Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties
29. Formulation technology to repurpose drugs for inhalation delivery
30. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology
31. Recent advances in prodrug-based nanoparticle therapeutics
32. Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes
33. Comment on: Inhaled antimicrobial therapy—Barriers to effective treatment, by J. Weers, Inhaled antimicrobial therapy — Barriers to effective treatment, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013☆
34. MP86-13 INCREASED PROSTATE CANCER DETECTION WITH MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION BIOPSY IN MEN REQUIRING REPEAT BIOPSY
35. Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia
36. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
37. Minimizing Variability of Cascade Impaction Measurements in Inhalers and Nebulizers
38. Modeling of a spray drying method to produce ciprofloxacin nanocrystals inside the liposomes utilizing a response surface methodology: Box-Behnken experimental design
39. Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats
40. Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts
41. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
42. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
43. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
44. Liposomal formulations for inhalation
45. Investigation of Protein-Surfactant Interactions by Analytical Ultracentrifugation and Electron Paramagnetic Resonance: The Use of Recombinant Human Tissue Factor as an Example
46. AERx®Pulmonary Drug Delivery Systems
47. No evidence of desensitization to repeat dosing with treprostinil palmitil inhalation suspension (TPIS) for 32-consecutive days in hypoxia-challenged telemetered rats
48. Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
49. Comparison of Treprostinil Palmitil Inhalation Suspension (TPIS) or Oral Sildenafil (Sild) in a Sugen/Hypoxia Rat Model of PAH
50. Hemodynamic and histological progression in the Sugen-Hypoxia Rat Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.